Rejected from Clinical Cancer Research? The 7 Best Journals to Submit Next

Source: Clarivate JCR 2024, AACR and journal author guidelines, and publisher journal pages (accessed June 2026). Impact-factor values are list metrics and the editorial fit reasons are our own assessment.

1. Cancer Research. This is the AACR basic-and-translational sister title and the most natural landing spot for technically strong work that lacked the clinical anchor Clinical Cancer Research demands. Cancer Research is for papers where the biological mechanism is the contribution; Clinical Cancer Research is for papers where the clinical insight is. If your reviewers praised the mechanism but questioned the patient relevance, this is usually the right step.

2. Molecular Cancer Therapeutics. The AACR sister for therapy-focused preclinical work: drug discovery, mechanism of sensitivity and resistance, target validation in models. It fits when the contribution is a candidate therapy or a resistance mechanism rather than a clinical result, and it carries the same AACR editorial culture you already formatted for.

3. British Journal of Cancer. A broad, well-cited general cancer journal that publishes discovery, translational, and clinical work across all tumor types. Its scope is wide enough to absorb a Clinical Cancer Research near-miss when the work is genuinely clinical or translational but did not clear the flagship's priority bar.

4. npj Precision Oncology. The open-access home for biomarker and precision-medicine work, with editors who treat targeted therapy and immunotherapy as the active center of the field. Reach for it when the contribution is a validated biomarker or a precision-treatment hypothesis and you can absorb a gold open-access APC.

5. Cancer Letters. Strong when the molecular and cell biology of cancer, including metastasis and signaling, is the real protagonist. It rewards mechanistic depth and moves relatively quickly, which suits work that is biology-first rather than clinic-first.

6. Oncogene. The right home when the core advance is oncogene mechanism, signaling, or tumor-suppression biology with no patient-facing data. Pick it when reviewers wanted deeper mechanism, not more clinical correlation.

7. Journal of Clinical Oncology. Reserve this for trial-grade, practice-changing clinical evidence. The IF (~41.9) is the highest on this list and the bar is correspondingly steep, so it suits work where a practicing oncologist would change what they do tomorrow, not a translational study with a clinical wrapper.

The AACR runs the Manuscript Transfer Service, and a Clinical Cancer Research decision letter declining a Research Article includes a link to the AACR transfer page in the SmartSubmit system. From there you can move your manuscript files, the peer review comments, and the reviewer identities to a second AACR journal of your choice.

The transfer page ranks the available AACR titles by subject terms plus journal metrics, and shows each title's publication costs, handling times, out-to-review rates, and acceptance rates. You can also upload a rebuttal letter explaining how you would address the reviewers' concerns. A transfer is a routing suggestion, not an endorsement: every transferred manuscript gets a fresh editorial assessment, and the AACR cannot guarantee review or publication at the second journal.

One mechanical detail matters. Once you confirm a transfer pathway, the link in the decision letter is disabled, so you cannot then bounce the same manuscript to a third AACR journal from that link. Choose the transfer destination deliberately the first time, and note that Cancer Research Communications accepts transfers only through its edit-and-resubmit pathway rather than as-is.

Practical ladder by rejection reason:

• Desk-rejected for scope or insufficient clinical significance? Do not transfer to another clinical-only AACR title unchanged. The clinical-relevance problem follows the paper. Move to the journal whose scope actually matches the work: Cancer Research or Molecular Cancer Therapeutics for mechanism, Oncogene for signaling biology, Cancer Letters for molecular cancer biology.

• Rejected for priority or incremental novelty but sound science? This is the classic transfer or step-down case.

British Journal of Cancer, npj Precision Oncology, or Cancer Research Communications via the AACR transfer is the next tier. Accept a transfer suggestion here if the recommended journal fits.

• Rejected after review for thin biomarker validation, weak clinical correlation, or an underpowered trial analysis? Fix it before resubmitting anywhere. Every serious oncology venue will raise the same point. Carry the revised validation and a rebuttal letter into the transfer or the manual resubmission.

In our pre-submission review work with Clinical Cancer Research manuscripts, the rejections we see most often cluster into four named patterns. Each is journal-specific and testable against your own manuscript, which is what makes them worth checking before you resubmit anywhere.

Preclinical work with no clinical bridge. Across our Clinical Cancer Research pre-submission reviews, the single most common trigger is a strong mechanism study, cell lines plus a mouse model plus a target, framed in the abstract as translational but with no patient samples, no clinical correlate, and no stated treatment decision it would inform.

Clinical Cancer Research exists for work that connects to the clinic, so editors route mechanism-only papers to Cancer Research at the desk. The fix is either real translational data (patient tissue, a clinical cohort, a biomarker tested against outcomes) or an honest reframing of the contribution as basic biology and a move to the right AACR sister.

This is testable: read your own abstract and ask whether a clinical oncologist would see a decision they could act on, or only a mechanism.

Biomarker claims without validation. A second recurring pattern is a candidate biomarker, a predictive signature, or a resistance marker reported in a single discovery cohort with no independent validation, no defined assay cutoff, and no link to a clinical endpoint. Clinical Cancer Research reviewers expect a biomarker to be validated in a second cohort and tied to response, resistance, or survival, with the statistical analysis matched to the design. A discovery-only association reads as preliminary.

Check that every biomarker claim has a validation cohort and a pre-specified cutoff, and that the survival or response analysis fits the data structure.

Underpowered or descriptive trial analysis. We see early-phase or retrospective clinical manuscripts where the central claim rests on a small, single-arm cohort with no power analysis, no correlative biomarker hypothesis, and conclusions that outrun the sample size. The journal favors trials accompanied by molecular or biomarker work that explains response, so a phase I result with no translational companion, or a retrospective series that restates known clinical patterns, gets filtered for priority.

Make sure the trial reporting follows CONSORT where applicable, that the sample size supports the conclusion, and that a biomarker or pharmacology hypothesis travels with the clinical data.

Scope drift into basic biology, epidemiology, or methods. The fourth pattern is a paper that is really oncogene mechanism, cancer epidemiology, or assay development wearing a clinical label. Clinical Cancer Research is not the AACR venue for pure mechanism (Cancer Research), preclinical drug work alone (Molecular Cancer Therapeutics), or population epidemiology without a clinical-decision link. When the manuscript's true center of gravity is one of those, the desk filter removes it fast, regardless of quality.

Read your introduction and discussion and ask: is a clinical or translational insight the actual protagonist, or a wrapper around a different field's question? If it is a wrapper, the right move is a different journal, not a resubmission.

Don't just resubmit the same file down the ladder. The fastest way to collect a second rejection is to send an unrevised manuscript to a journal that screens for the same thing Clinical Cancer Research did, and some manuscripts need real work, not a faster next submission. A desk rejection for scope or clinical significance is a routing problem you can fix by choosing the right AACR or external journal and reframing the contribution.

A post-review rejection for thin biomarker validation, weak clinical correlation, or an underpowered analysis is a substance problem, and the same reviewers' concerns will reappear at any serious oncology venue. Be honest about which one you got.

Two cases call for real work before resubmitting, not a faster next submission. First, if reviewers questioned whether the result is clinically meaningful, the manuscript needs the biomarker validation, the clinical correlate, or the translational companion it was missing. Second, if the trial design or statistics were challenged, new analysis (and sometimes new data) is the only fix.

Appealing is rarely worth it: a clinical-significance or priority rejection is an editorial judgment, not a factual error, and the appeal queue is slower than a clean transfer or resubmission to a better-fit journal.